AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26170395 — intervention group
Group type: COMPARATOR
Intervention: Single dose of albendazole
Number of subjects: 2436
Study 25129877 — intervention group
Group type: EXPERIMENTAL
Intervention: <1 drink/day
Number of subjects: 449
Study 25129877 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 to 2 drinks/day
Number of subjects: 449
Study 25129877 — intervention group
Group type: EXPERIMENTAL
Intervention: 3+ drinks/day
Number of subjects: 449
Study 25129877 — intervention group
Group type: COMPARATOR
Intervention: none
Number of subjects: 449
Study 23395006 — intervention group
Group type: EXPERIMENTAL
Intervention: Guide to Decide (GtD)
Number of subjects: 1012
Study 23395006 — intervention group
Group type: COMPARATOR
Intervention: Time 1 control
Number of subjects: 1012
Study 23395006 — intervention group
Group type: COMPARATOR
Intervention: 3‐month control
Number of subjects: 1012
Study 20801542 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 52
Study 20801542 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 52
Study 18361808 — intervention group
Group type: EXPERIMENTAL
Intervention: Double balloon kyphoplasty
Number of subjects: 51
Study 18361808 — intervention group
Group type: EXPERIMENTAL
Intervention: Single balloon kyphoplasty
Number of subjects: 51
Study 16289984 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively charged oil/water nanoemulsions containing ceramide 3B and SC lipids (PNSC)
Number of subjects: 42
Study 16289984 — intervention group
Group type: COMPARATOR
Intervention: Physiogel cream (control)
Number of subjects: 42
Study 16289984 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively charged o/w nanoemulsion and SC lipids (NNSC)
Number of subjects: 42
Study 16289984 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively charged oil/water nanoemulsions (PN)
Number of subjects: 42
Study 15127991 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered Brånemark System Mark IV fixture (97 implants)
Number of subjects: 40
Study 15127991 — intervention group
Group type: COMPARATOR
Intervention: Brånemark Standard or Mark II implants (92 implants)
Number of subjects: 40
Study 15127991 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Mark IV and control implants)
Number of subjects: 40
Study 11038030 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly schedule of 5-fluorouracil and L-folinic acid
Number of subjects: 4927
Study 11038030 — intervention group
Group type: COMPARATOR
Intervention: Four-weekly schedule of 5-fluorouracil and L-folinic acid
Number of subjects: 4927
Study 8815692 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine mesylate (DLV)
Number of subjects: 1000
Study 1356646 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (ATR) - loading dose 0.25 mg.kg‐1, infusion at 5.0 micrograms.kg‐1.min‐1
Number of subjects: 50
Study 1356646 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium (VEC) - loading dose 0.05 mg.kg‐1, infusion at 1.0 microgram.kg‐1.min‐1
Number of subjects: 50
Study 3910768 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg administered 1 hour before a standardized breakfast
Number of subjects: 18
Study 3910768 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg administered together with a standardized breakfast
Number of subjects: 18
Study 3910768 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for 2 weeks prior to captopril
Number of subjects: 18
Study 30486575 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 s cryoablation (Group C)
Number of subjects: 32
Study 30486575 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-minute cryoablation (Group D)
Number of subjects: 32
Study 30486575 — intervention group
Group type: COMPARATOR
Intervention: Tracheotomy alone (Group A)
Number of subjects: 32
Study 30486575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-tracheal brush rubbing (Group B)
Number of subjects: 32
Study 27537754 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g IV paracetamol
Number of subjects: 21
Study 27537754 — intervention group
Group type: COMPARATOR
Intervention: 1 g oral paracetamol
Number of subjects: 21
Study 27537754 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g oral paracetamol
Number of subjects: 21
Study 25434143 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education path intervention
Number of subjects: 60
Study 22854666 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg hepatitis B vaccine
Number of subjects: 81
Study 22854666 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg hepatitis B vaccine
Number of subjects: 81
Study 22854666 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose at year 23
Number of subjects: 81
Study 22854666 — intervention group
Group type: COMPARATOR
Intervention: Overall study findings
Number of subjects: 81
Study 20172654 — intervention group
Group type: EXPERIMENTAL
Intervention: 25mg of amitriptyline
Number of subjects: 118
Study 20172654 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 118
Study 18401269 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted inferior turbinoplasty with lateralization (MAITL)
Number of subjects: 160
Study 18401269 — intervention group
Group type: COMPARATOR
Intervention: Submucosal resection (SR)
Number of subjects: 160
Study 16036433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal BDNF (25 or 150 microg/day)
Number of subjects: 10
Study 16036433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal BDNF
Number of subjects: 10
Study 16036433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12622499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 20 mg intravenous bolus via patient-controlled analgesia device
Number of subjects: 44
Study 12622499 — intervention group
Group type: COMPARATOR
Intervention: Morphine 2 mg intravenous bolus via patient-controlled analgesia device
Number of subjects: 44
Study 10676043 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene, specific dosage and duration not available
Number of subjects: 0
Study 7547044 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritonsillar infiltration with tenoxicam 5 mg in 8 ml of normal saline (4 ml per tonsil)
Number of subjects: 50
Study 7547044 — intervention group
Group type: COMPARATOR
Intervention: Normal saline only (placebo)
Number of subjects: 50
Study 1778925 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF, 9 mg/kg)
Number of subjects: 7
Study 6754118 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin ethyl succinate (paediatric dosage)
Number of subjects: 169
Study 6754118 — intervention group
Group type: COMPARATOR
Intervention: Topical 1% tetracycline ointment
Number of subjects: 169
Study 31801155 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate characteristic (HRC) index 12 hours prior to diagnosis of UTI
Number of subjects: 2989
Study 31801155 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate characteristic (HRC) index 12 hours prior to diagnosis of BSI
Number of subjects: 2989
Study 31801155 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HRC index for meningitis
Number of subjects: 2989
Study 30572905 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (15-20 mg/kg daily for six months)
Number of subjects: 1556
Study 30572905 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for six months)
Number of subjects: 1556
Study 27573335 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet computer with the Breathing Easier Support Toolkit (BEST)
Number of subjects: 71
Study 27573335 — intervention group
Group type: COMPARATOR
Intervention: Traditional method for teaching breathing techniques
Number of subjects: 71
Study 24581407 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-stretch compression bandaging
Number of subjects: 8
Study 24581407 — intervention group
Group type: EXPERIMENTAL
Intervention: High-stretch compression bandaging
Number of subjects: 8
Study 24581407 — intervention group
Group type: COMPARATOR
Intervention: Baseline phase
Number of subjects: 8
Study 22213304 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (oral) 60 mg/m² on days 1, 8, 15 every 4 weeks for 4 cycles (group A)
Number of subjects: 74
Study 22213304 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (intravenous) 90 mg/m² for 1 h on days 1, 8, 15 every 4 weeks for a total of 4 cycles (group B)
Number of subjects: 74
Study 20145555 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training at 35 Hz for 5 minutes twice a week
Number of subjects: 0
Study 20145555 — intervention group
Group type: COMPARATOR
Intervention: Isometric contraction stress (Control)
Number of subjects: 0
Study 17384205 — intervention group
Group type: EXPERIMENTAL
Intervention: Vysis AutoVysion System
Number of subjects: 39
Study 16088080 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan
Number of subjects: 25
Study 16088080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12106923 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-A group (medication + LDL-A, n = 11)
Number of subjects: 18
Study 12106923 — intervention group
Group type: COMPARATOR
Intervention: Medication group (medication only, n = 7)
Number of subjects: 18
Study 10579259 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium:oxygen
Number of subjects: 19
Study 10579259 — intervention group
Group type: COMPARATOR
Intervention: Air:oxygen
Number of subjects: 19
Study 8907093 — intervention group
Group type: EXPERIMENTAL
Intervention: IA + SM + CT
Number of subjects: 48
Study 8907093 — intervention group
Group type: COMPARATOR
Intervention: IA + SM + SC
Number of subjects: 48
Study 1858944 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion (0.855 M, 0.06 ml.min‐1.kg‐1)
Number of subjects: 7
Study 1858944 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline infusion (0.154 M, 0.06 ml.min‐1.kg‐1)
Number of subjects: 7
Study 1858944 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion (0.855 M)
Number of subjects: 7
Study 6134885 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 62
Study 6134885 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein cow's milk
Number of subjects: 62
Study 6134885 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted formula
Number of subjects: 62
Study 6134885 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein cow's milk
Number of subjects: 62
Study 6134885 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based formula
Number of subjects: 62
Study 31174494 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone app-based cognitive behaviour training (CBT) for 6 weeks, with weekly theme modules including learning content and assignments.
Number of subjects: 120
Study 31174494 — intervention group
Group type: COMPARATOR
Intervention: Usual postpartum care content through the App.
Number of subjects: 120
Study 29742990 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA%SOFIT estimates from direct observation protocols
Number of subjects: 35
Study 29742990 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA%perm estimates based on permutations of students and observation order
Number of subjects: 35
Study 29742990 — intervention group
Group type: EXPERIMENTAL
Intervention: Differences in MVPA% estimates between randomly selected groups of lessons
Number of subjects: 35
Study 26962852 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc)
Number of subjects: 62
Study 25152290 — intervention group
Group type: EXPERIMENTAL
Intervention: Coopdech bronchial blocker (group A)
Number of subjects: 40
Study 25152290 — intervention group
Group type: COMPARATOR
Intervention: Double-lumen tube (group B)
Number of subjects: 40
Study 22873532 — intervention group
Group type: EXPERIMENTAL
Intervention: R-FC (rituximab, fludarabine, and cyclophosphamide)
Number of subjects: 560
Study 22873532 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 560
Study 22873532 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (maintenance therapy)
Number of subjects: 560
Study 22873532 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa (maintenance therapy)
Number of subjects: 560
Study 22873532 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP followed by rituximab maintenance
Number of subjects: 560
Study 22873532 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP followed by interferon alfa maintenance
Number of subjects: 560
Study 21209539 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume preload of 1000 ml of Ringer's lactate solution
Number of subjects: 40
Study 21209539 — intervention group
Group type: COMPARATOR
Intervention: No volume preload
Number of subjects: 40
Study 17116398 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical extended mediastinal lymphadenectomy (TEMLA)
Number of subjects: 41
Study 17116398 — intervention group
Group type: COMPARATOR
Intervention: Cervical mediastinoscopy (CM)
Number of subjects: 41
Study 15657860 — intervention group
Group type: EXPERIMENTAL
Intervention: Precut papillotomy
Number of subjects: 62
Study 15657860 — intervention group
Group type: COMPARATOR
Intervention: Persistence with non-wire-guided, single-lumen papillotome
Number of subjects: 62
Study 12405614 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with chronic low back pain (CLBP)
Number of subjects: 21
Study 12405614 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 21
Study 12405614 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondepressed participants with CLBP
Number of subjects: 21
Study 12405614 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed participants with CLBP
Number of subjects: 21
Study 11578786 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 6906
Study 11578786 — intervention group
Group type: COMPARATOR
Intervention: Standard enucleation
Number of subjects: 6906
Study 9556921 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Posturography (DP)
Number of subjects: 14
Study 9556921 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Perturbed Posturography (RPP)
Number of subjects: 14
Study 9556921 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement Coordination (MC)
Number of subjects: 14
Study 9556921 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 14
Study 7569625 — intervention group
Group type: EXPERIMENTAL
Intervention: Chagas' infection (serologic evidence)
Number of subjects: 372
Study 7569625 — intervention group
Group type: EXPERIMENTAL
Intervention: Chagas' infection (with EKG alterations)
Number of subjects: 372
Study 7569625 — intervention group
Group type: COMPARATOR
Intervention: Negative serologic test (with EKG alterations)
Number of subjects: 372
Study 7569625 — intervention group
Group type: EXPERIMENTAL
Intervention: Chagas' infection (intraventricular conduction defects)
Number of subjects: 372
Study 2691479 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate (1,000 mg amoxycillin + 250 mg clavulanate) tds
Number of subjects: 40
Study 2691479 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg) bd
Number of subjects: 40
Study 2691479 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 1101707 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 44
Study 1101707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 6154334 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic cardioplegic solution (200-1000 ml) infused into the ascending aorta during cardiopulmonary bypass.
Number of subjects: 41
Study 31764793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide (1 mg, 4 ml) for 15 minutes before bronchoscopy
Number of subjects: 250
Study 31764793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 29688425 — intervention group
Group type: EXPERIMENTAL
Intervention: PST (grazed perennial crested wheatgrass and native range before feedlot entry)
Number of subjects: 144
Study 29688425 — intervention group
Group type: EXPERIMENTAL
Intervention: ANN (grazed perennial crested wheatgrass and native range, then field pea-barley mix and unharvested corn before feedlot entry)
Number of subjects: 144
Study 29688425 — intervention group
Group type: COMPARATOR
Intervention: FLT (feedlot)
Number of subjects: 144
Study 26946208 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliances (MAAs) used for 12 consecutive months
Number of subjects: 28
Study 26946208 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intraoral device or treatment)
Number of subjects: 28
Study 25231382 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose (PDX) fiber
Number of subjects: 12
Study 22714779 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical (S)-ketamine
Number of subjects: 12
Study 22714779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19596382 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta 1a sc
Number of subjects: 0
Study 19596382 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta 1b sc
Number of subjects: 0
Study 19596382 — intervention group
Group type: COMPARATOR
Intervention: Interferon-beta 1a im
Number of subjects: 0
Study 19596382 — intervention group
Group type: COMPARATOR
Intervention: Glatiramer acetate
Number of subjects: 0
Study 18044287 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg/kg
Number of subjects: 69
Study 18044287 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil 20 microg/kg
Number of subjects: 69
Study 18044287 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 2 microg/kg
Number of subjects: 69
Study 16225527 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin (1.3, 2.6, and 3.9 mg/day)
Number of subjects: 881
Study 16225527 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oxybutynin (3.9 mg/day)
Number of subjects: 881
Study 16225527 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release tolterodine (4 mg/day)
Number of subjects: 881
Study 16225527 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day diaries
Number of subjects: 881
Study 16225527 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day diaries
Number of subjects: 881
Study 11805650 — intervention group
Group type: EXPERIMENTAL
Intervention: Active straight leg raise
Number of subjects: 26
Study 11805650 — intervention group
Group type: EXPERIMENTAL
Intervention: Active straight leg raise with manual compression through the ilia
Number of subjects: 26
Study 11805650 — intervention group
Group type: COMPARATOR
Intervention: Control group (pain-free subjects)
Number of subjects: 26
Study 10068415 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intravenous infusion of 60 microg of prostaglandin E1 (alprostadil‐alpha‐cyclodextrine)
Number of subjects: 1560
Study 10068415 — intervention group
Group type: COMPARATOR
Intervention: No prostaglandin E1
Number of subjects: 1560
Study 7782873 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional development program for Clinical Nurses
Number of subjects: 0
Study 7782873 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1959538 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO at 10 units/kg
Number of subjects: 16
Study 1959538 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO at 100 units/kg
Number of subjects: 16
Study 1959538 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (all doses)
Number of subjects: 16
Study 1959538 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO at 25-50 units/kg
Number of subjects: 16
Study 1959538 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (doses greater than 25 units/kg)
Number of subjects: 16
Study 6955123 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional toothcleaning every 2 weeks for 18 months
Number of subjects: 104
Study 6955123 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction and practice in proper toothcleaning techniques
Number of subjects: 104
Study 6955123 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 104
Study 31820002 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 255
Study 31820002 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education (HE)
Number of subjects: 255
Study 31820002 — intervention group
Group type: COMPARATOR
Intervention: Brief Advice (BA)
Number of subjects: 255
Study 31275984 — intervention group
Group type: EXPERIMENTAL
Intervention: IT > 10 Ncm (G1)
Number of subjects: 31
Study 31275984 — intervention group
Group type: EXPERIMENTAL
Intervention: IT ≥ 10Ncm and ≤ 30 Ncm (G2)
Number of subjects: 31
Study 31275984 — intervention group
Group type: EXPERIMENTAL
Intervention: IT >30Ncm and < 45Ncm (G3)
Number of subjects: 31
Study 31275984 — intervention group
Group type: EXPERIMENTAL
Intervention: IT ≥ 45Ncm (G4)
Number of subjects: 31
Study 31275984 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 31
Study 29984430 — intervention group
Group type: EXPERIMENTAL
Intervention: Mystery shop intervention with monthly feedback to clerks and servers.
Number of subjects: 557
Study 29984430 — intervention group
Group type: EXPERIMENTAL
Intervention: Mystery shop intervention for on-premises establishments.
Number of subjects: 557
Study 29984430 — intervention group
Group type: EXPERIMENTAL
Intervention: Mystery shop intervention for off-premises establishments.
Number of subjects: 557
Study 26796803 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX regimen
Number of subjects: 107
Study 26796803 — intervention group
Group type: COMPARATOR
Intervention: SOX regimen
Number of subjects: 107
Study 26796803 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX regimen in TP-positive patients
Number of subjects: 107
Study 26796803 — intervention group
Group type: COMPARATOR
Intervention: SOX regimen in DPD-positive patients
Number of subjects: 107
Study 24525690 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (200 mg daily for 12 weeks)
Number of subjects: 138
Study 24525690 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 138